Despite the potential clinical implications of EGFR compound mutations, most of the previous studies were based on limited patient cohorts, so it is imperative to perform large-scale analyses to gain a deeper insight into the complexity and diversity of compound EGFR mutations in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.